GoldBamboo.com - Knowledge is strong medicine
  

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosupression (BENEFIT) - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:






Diabetic Kidney Problems

 




Clinical Trial: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosupression (BENEFIT)

This study is not yet open for patient recruitment.
Verified by Bristol-Myers Squibb December 2005

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00256750

Purpose

The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kindney transplantation while avoiding some of the toxic effects of standard immunosupressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.
Condition Intervention Phase
Kidney Transplantation
Chronic Kidney Failure
 Drug: Belatacept
Phase III

MedlinePlus related topics:  Kidney Failure

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)

Further study details as provided by Bristol-Myers Squibb:
Primary Outcomes: The composite of subject and graft survival by 12 months.; The composite of measured GFR <60ml/min/1.73 m2 at Month 12 or a decrease in measured GFR >= 10mL/min/1.73m2 from Month 3 to Month 12.; The incidence of acute rejection by 12 months
Secondary Outcomes: Measured GFR at 12 months.; Biopsy-proven chronic allografnephropathy at 12 months.
Expected Total Enrollment:  660

Study start: December 2005

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • The subject is a recipient of a living donor or deceased donor kidney transplant.

    • Male or Female, 18 or older

Exclusion Criteria:

  • First time recipient, PRA >- 50% or for retransplantation PRA >- 30%.
  • If retransplantation, previous graft loss cannot be due to acute rejection.
  • Positve cross match.
  • Subject receiveing extended criteria donor (ECD) organ

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00256750

BMS Call Center      1-866-892-1BMS  Ext. 323 
BMS Call Center Outside the US and Canada      1-941-906-4711  Ext. 323 

Alabama
      Local Institution, Birmingham,  Alabama,  United States

California
      Local Institution, Loma Linda,  California,  United States

      Local Institution, Los Angeles,  California,  United States

      Local Institution, San Diego,  California,  United States

      Local Institution, San Francisco,  California,  United States

Colorado
      Local Institution, Denver,  Colorado,  United States

Connecticut
      Local Institution, New Haven,  Connecticut,  United States

Florida
      Local Institution, Gainsville,  Florida,  United States

      Local Institution, Miami,  Florida,  United States

Georgia
      Local Institution, Atlanta,  Georgia,  United States

      Local Institution, Augusta,  Georgia,  United States

Illinois
      Local Institution, Chicago,  Illinois,  United States

Indiana
      Local Institution, Indianapolis,  Indiana,  United States

Kentucky
      Local Institution, Lexington,  Kentucky,  United States

Louisiana
      Local Institution, New Orleans,  Louisiana,  United States

Maine
      Local Institution, Portland,  Maine,  United States

Maryland
      Local Institution, Baltimore,  Maryland,  United States

      Local Institution, Bethesda,  Maryland,  United States

Massachusetts
      Local Institution, Boston,  Massachusetts,  United States

Michigan
      Local Institution, Ann Arbor,  Michigan,  United States

      Local Institution, Detroit,  Michigan,  United States

Minnesota
      Local Institution, Minneapolis,  Minnesota,  United States

Missouri
      Local Institution, St. Louis,  Missouri,  United States

New Jersey
      Local Institution, Livingston,  New Jersey,  United States

New York
      Local Institution, Albany,  New York,  United States

      Local Institution, New York,  New York,  United States

      Local Institution, Rochester,  New York,  United States

North Carolina
      Local Institution, Chapel Hill,  North Carolina,  United States

      Local Institution, Charlotte,  North Carolina,  United States

      Local Institution, Durham,  North Carolina,  United States

      Local Institution, Winston Salem,  North Carolina,  United States

Ohio
      Local Institution, Cincinnati,  Ohio,  United States

      Local Institution, Cleveland,  Ohio,  United States

Pennsylvania
      Local Institution, Philadelphia,  Pennsylvania,  United States

South Carolina
      Local Institution, Charleston,  South Carolina,  United States

Tennessee
      Local Institution, Nashville,  Tennessee,  United States

Texas
      Local Institution, Dallas,  Texas,  United States

      Local Institution, Houston,  Texas,  United States

Utah
      Local Institution, Salt Lake City,  Utah,  United States

Vermont
      Local Institution, Burlington,  Vermont,  United States

Virginia
      Local Institution, Charlottesville,  Virginia,  United States

      Local Institution, Falls Church,  Virginia,  United States

      Local Institution, Norfolk,  Virginia,  United States

Washington
      Local Institution, Spokane,  Washington,  United States

      Local Institution, Seattle,  Washington,  United States

Wisconsin
      Local Institution, Madison,  Wisconsin,  United States

      Local Institution, Milwaukee,  Wisconsin,  United States

Argentina
      Local Institution, Buenos Aires,  Argentina

      Local Institution, Cordoba,  Argentina

      Local Institution, Santa Fe,  Argentina

Argentina, Buenos Aires
      Local Institution, Capital Federal,  Buenos Aires,  Argentina

Australia, New South Wales
      Local Institution, Camperdown,  New South Wales,  Australia

      Local Institution, Westmead,  New South Wales,  Australia

Australia, Queensland
      Local Institution, Wolloongabba,  Queensland,  Australia

Australia, South Australia
      Local Institution, Woodville,  South Australia,  Australia

Australia, Victoria
      Local Institution, Parkville,  Victoria,  Australia

Austria
      Local Institution, Graz,  Austria

      Local Institution, Innsbruck,  Austria

      Local Institution, Vienna,  Austria

Belgium
      Local Institution, Ghent,  Belgium

      Local Institution, Leuven,  Belgium

Brazil
      Local Institution, Rio de Janeiro,  Brazil

      Local Institution, Sao Paulo,  Brazil

Brazil, Rio Grande Do Sul
      Local Institution, Porto Alegre,  Rio Grande Do Sul,  Brazil

Brazil, San Paulo
      Local Institution, San Paulo - SP,  San Paulo,  Brazil

Brazil, Sao Paulo
      Local Institution, Campinas - SP,  Sao Paulo,  Brazil

Canada, Alberta
      Local Institution, Edmonton,  Alberta,  Canada

Canada, Nova Scotia
      Local Institution, Halifax,  Nova Scotia,  Canada

Canada, Quebec
      Local Institution, Montreal,  Quebec,  Canada

Canada, Saskatchewan
      Local Institution, Saskatoon,  Saskatchewan,  Canada

Czech Republic
      Local Institution, PRAGUE 4,  Czech Republic

France
      Local Institution, Bordeaux,  France

      Local Institution, Brest,  France

      Local Institution, Creteil,  France

      Local Institution, La Tronche Grenoble,  France

      Local Institution, Le Kremlin-Bicetre,  France

      Local Institution, Nante Cedex 01,  France

      Local Institution, Toulouse,  France

Germany
      Local Institution, Berlin,  Germany

      Local Institution, Erlangen,  Germany

      Local Institution, Essen,  Germany

      Local Institution, Hannover,  Germany

      Local Institution, Heidelberg,  Germany

Hungary
      Local Institution, Budapest,  Hungary

      Local Institution, Pecs,  Hungary

      Local Institution, Szeged,  Hungary

Israel
      Local Institution, Petah Tikva,  Israel

Italy
      Local Institution, Bergamo,  Italy

      Local Institution, Milano,  Italy

      Local Institution, Padova,  Italy

      Local Institution, Roma,  Italy

Mexico
      Local Institution, Aguascalientes,  Mexico

      Local Institution, Distrito Federal,  Mexico

Mexico, Distrito Federal
      Local Institution, Mexico City,  Distrito Federal,  Mexico

Mexico, Morelos
      Local Institution, Cuernavaca,  Morelos,  Mexico

Mexico, San Luis Potosi
      Local Institution, Zona Universitaria,  San Luis Potosi,  Mexico

Norway
      Local Institution, Oslo,  Norway

South Africa, Gauteng
      Local Institution, Pretoria,  Gauteng,  South Africa

South Africa, Kwa Zulu Natal
      Local Institution, Durban,  Kwa Zulu Natal,  South Africa

South Africa, Western Cape
      Local Institution, Observatory,  Western Cape,  South Africa

Spain
      Local Institution, Barcelona,  Spain

      Local Institution, Madrid,  Spain

      Local Institution, S/N Malaga,  Spain

Sweden
      Local Institution, Gothenburg,  Sweden

Switzerland
      Local Institution, Geneve,  Switzerland

United Kingdom, Glamorgan
      Local Institution, Cardiff,  Glamorgan,  United Kingdom

United Kingdom, Greater London
      Local Institution, London,  Greater London,  United Kingdom

United Kingdom, Lancashire
      Local Institution, Manchester,  Lancashire,  United Kingdom

United Kingdom, West Midlands
      Local Institution, Birmingham,  West Midlands,  United Kingdom

More Information

Study ID Numbers:  IM103-008
Last Updated:  December 21, 2005
Record first received:  November 15, 2005
ClinicalTrials.gov Identifier:  NCT00256750
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10


[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Diabetic Kidney Problems.

November 25, 2009



Page Updated: September 6, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.